NovoCure Ltd
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M |
| Cost of revenue | $166.9M | $137.2M | $128.3M | $114.9M | $114.9M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M |
| Research and development | $224.5M | $209.6M | $223.1M | $206.1M | $201.3M |
| Operating expenses | $642.3M | $638.5M | $613.9M | $512.5M | $464.5M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M |
| Interest expense | $22.2M | $11.7M | $4.9M | $8.1M | $8.8M |
| Pretax income | -$136.2M | -$131.2M | -$191.7M | -$81.8M | -$52.1M |
| Income tax expense | -$23,000 | $37.5M | $15.3M | $10.7M | $6.3M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M |
| Balance Sheet | |||||
| Cash and equivalents | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M |
| Current assets | $646.7M | $1.1B | $1.0B | $1.1B | $1.1B |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B | $1.1B |
| Current liabilities | $223.2M | $756.4M | $179.1M | $158.8M | $142.6M |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M |
| Stockholders' equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M |
| Depreciation and amortization | $9.4M | $6.2M | $3.9M | $3.1M | $2.8M |
| Stock-based compensation | $104.8M | $160.0M | $115.6M | $107.0M | $94.9M |
| Capital expenditure | $26.6M | $42.9M | $27.1M | $21.4M | $24.2M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M |
| Impairments | $4.9M | $1.2M | $493,000 | $955,000 | $649,000 |
Shares outstanding 115.8M · Free float 63.2%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.